Kim Myung Ae, Choi Soon Il, Kim Jong Min, Oh Hyun Sub, You Yong Sung, Lee Won Ki, Kim Soon Hyun, Kwon Oh Woong, Kim Ju Young
Retina Center, Nune Eye Hospital, Seoul, Korea.
Korean J Ophthalmol. 2025 Jun;39(3):213-221. doi: 10.3341/kjo.2024.0125. Epub 2025 Apr 16.
To investigate the outcomes of brolucizumab reinjection after intraocular inflammation (IOI) development.
This retrospective study analyzed patients with brolucizumab injections from April 2021 to January 2024. Patients who developed IOI after brolucizumab were included and categorized into subgroups depending on reinjection, discontinuation, and further IOI development.
A total of 472 eyes of 432 patients received brolucizumab injections. Thirty-eight cases developed IOI at least once, and 25 continued brolucizumab. Sixteen cases had no more IOI events, and nine experienced a second or more IOI events. Among the nine cases, three maintained brolucizumab injections despite IOI recurrence. The incidence of IOI was 8.1% based on the number of eyes (38 of 472 eyes) and 2.0% based on the number of brolucizumab injections (50 of 2,468 injections). The incidence of occlusive retinal vasculitis was 0.2% (1 of 472 eyes). The recurrence rate was 23.7% (9 of 38 eyes). The average number of injections between the first brolucizumab injection and the injection date on which IOI first developed was 2.15 times in the no-reinjection group, 3.44 times in the no-IOI-recurrence group, and 2.0 times in the second-IOI-episode group. Time to IOI occurrence in cases with first IOI episode was 18.60 ± 16.73 days, with 15 cases developing IOI within 1 week.
This study elucidates the real-world incidence of brolucizumab associated IOIs, with a description of information related to reinjections after the IOI episodes. A comprehensive understanding of brolucizumab reinjection is essential for its optimal utilization.
探讨眼内炎（IOI）发生后注射布罗卢izumab的疗效。
这项回顾性研究分析了2021年4月至2024年1月接受布罗卢izumab注射的患者。纳入布罗卢izumab治疗后发生IOI的患者，并根据再次注射、停药和进一步发生IOI进行亚组分类。
432例患者的472只眼接受了布罗卢izumab注射。38例至少发生过一次IOI，25例继续使用布罗卢izumab。16例未再发生IOI事件，9例经历了第二次或更多次IOI事件。在这9例中，3例尽管IOI复发仍维持布罗卢izumab注射。基于眼数（472只眼中的38只），IOI的发生率为8.1%；基于布罗卢izumab注射次数（2468次注射中的50次），发生率为2.0%。闭塞性视网膜血管炎的发生率为0.2%（472只眼中的1只）。复发率为23.7%（38只眼中的9只）。首次布罗卢izumab注射至首次发生IOI的注射日期之间的平均注射次数，未再次注射组为2.15次；未发生IOI复发组为3.44次；第二次发生IOI组为2.0次。首次发生IOI的病例中，IOI发生时间为18.60±16.73天，15例在1周内发生IOI。
本研究阐明了布罗卢izumab相关IOI的真实发生率，并描述了IOI发作后再次注射的相关信息。全面了解布罗卢izumab再次注射对于其优化使用至关重要。
